FDA decisions and breakthrough oncology data are reshaping cancer treatment, with growing enthusiasm around IMNN-001, a DNA-based immunotherapy under investigation for ovarian cancer.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
The Targeted Pulse: FDA Decisions and Breakthrough Data Shape Oncology Landscape | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
IMNN-001 (DNA-Based Immunotherapy) Investigational therapy
Ovarian Cancer Target disease
Clinical Investigation Development stage